BioSpace News Archive

Business

9 Top Biopharma CEO-to-Employee Pay Gaps

Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.

May 21, 2024
·
9 min read
·
Tristan Manalac
FDA

FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea

The regulator on Monday approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.

May 21, 2024
·
2 min read
·
Tristan Manalac
Policy

BIO Axes 30 Staff in Realignment as Congress Advances BIOSECURE Act

Following its recent about-face on the BIOSECURE Act, designed to combat China’s influence in the biopharma industry, lobbying group Biotechnology Innovation Organization in a realignment is laying off 30 employees.

May 21, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Sanofi, Regeneron Post Strong Phase III COPD Data for Dupixent as FDA Decision Looms

Late-stage results from the NOTUS trial showed Sanofi and Regeneron’s Dupixent lowered moderate to severe chronic obstructive pulmonary disease exacerbations by 34% and led to significantly better lung function.

May 21, 2024
·
2 min read
·
Tristan Manalac
Business

AstraZeneca Sets $80B Revenue Target, Goal of 20 New Drugs by 2030

AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.

May 21, 2024
·
2 min read
·
Tristan Manalac
Policy

Opinion: Chinese CDMOs and US Biopharma PR Strike a Precarious Balance

The PR departments of Chinese CDMOs affected by the BIOSECURE Act and their U.S. partners must step up to ensure proposed legislation doesn’t squash innovation.

May 21, 2024
·
5 min read
·
JX (Jaxon) Tan
Business

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology

Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up in 2024.

May 21, 2024
·
2 min read
·
Kate Goodwin
Drug Development

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate

Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.

May 21, 2024
·
2 min read
·
Tyler Patchen
Drug Development

GSK’s Long-Acting Asthma Drug Hits Primary Endpoint in Phase III Trials

Participants experienced fewer asthma attacks when receiving the antibody every six months, GSK said Tuesday, positioning the company to file for approval of the potential blockbuster.

May 21, 2024
·
2 min read
·
Nick Paul Taylor
Opinion: Annexon Tackles Guillain-Barre, Other Inflammatory Diseases with Novel Antibody

With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for Guillain-Barre syndrome with its investigational antibody, ANX005. The candidate is also being trialed in Huntington disease and ALS.

May 21, 2024
·
3 min read
·
Jia Jie Chen